Autres langues KalVista Pharmaceuticals, Inc.

Actions

KALV

US4834971032

Temps réel estimé Cboe BZX Autres places de cotation 18:07:22 19/04/2024			Varia. 5j.	Varia. 1 janv.
11,56 ^USD	+0,57 %		-3,53 %	-6,37 %

18/03	KalVista Pharmaceuticals présente des données réelles sur le fardeau du traitement et l'évolution de l'AOH lors de la 2024 HAEi Regional Conference Americas	CI
11/03	KalVista Pharmaceuticals, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois clos le 31 janvier 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04
Certain performance stock options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04
Certain restricted stock units of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04
Certain Stock Options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	15/04
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	03/04
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference	03/04
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	18/03
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	18/03
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine Designation for Sebetralstat	13/03
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat	12/03
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	11/03
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update	11/03
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	08/03
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	08/03
KalVista Pharmaceuticals Names Benjamin Palleiko as CEO	07/03
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer	07/03
KalVista Pharmaceuticals, Inc. Announces Board Changes	07/03
KalVista Pharmaceuticals, Inc. Announces Chief Executive Officer Changes	07/03
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference	06/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues KalVista Pharmaceuticals, Inc.

Actions

KALV

US4834971032

Autres langues

Filtres